siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model

Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Jae Yun, Ryu, Hyun Jin, Lee, Seung-Hwan, Kim, Dong-Young, Kim, Myung Ji, Lee, Eun Ji, Ryu, Yeon-Mi, Kim, Sang-Yeob, Kim, Kyu-Pyo, Choi, Eun Young, Ahn, Hyung Jun, Chang, Suhwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534711/
https://www.ncbi.nlm.nih.gov/pubmed/34685714
http://dx.doi.org/10.3390/cells10102734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534711/
https://www.ncbi.nlm.nih.gov/pubmed/34685714
http://dx.doi.org/10.3390/cells10102734

Ejemplares similares